StemCell Therapy

Orbicare signs with the Health Travel Technologies global patient referral application to enable millions of patients access to the best, most affordable medical care throughout Latin America and Europe.

San Francisco, California (PRWEB) January 31, 2012

Few would argue that the US health care system is sick, and physician-founded Orbicare of Miami is betting that Silicon Valley's Health Travel Technologies (HTT) has the cure with its global patient referral application.

The partnership between Orbicare and Health Travel Technologies connects US patients with international doctors like never before, saving thousands on the cost of necessary and cosmetic medical, dental and surgical care.

HTT is the creator of Inpatra™, the world’s most comprehensive global patient referral and management application. HTT has signed a licensing agreement with Orbicare, a leader in international patient referral, to host its comprehensive portfolio of medical services.

The partnership will provide English- and Spanish-speaking US patients and employers with high quality health care alternatives across Latin America and Europe, including medical and dental travel programs in Argentina, Costa Rica, Panama, Spain and Turkey.

“HTT helps international health care networks work directly with US patients and employers to provide much needed access to affordable health care” said Health Travel Technologies CEO Herb Stephens.

“In addition to high quality, high value medical care, an added bonus for American patients and employers is the proximity and safety of the Orbicare health care network,” said Stephens.

“Orbicare searched for the right partner for more than a year,” says Teresa Arenas, Chief Operations Officer for Orbicare. “We chose HTT for its comprehensive technology, unmatched experience and dedicated people.

“The Inpatra™ international patient referral and management application provides Orbicare with the hosted business processes we need, so that we can focus our resources on our strengths: providing personalized, quality medical services to US patients and employer benefits plans, especially during this time of rapid expansion.”

HTT is the largest technology and services company in the health information technology space, processing more than 1 million international travelers representing more than $500 million in financial transactions per year, with health travel representing double digit year-over-year growth.

About Orbicare

The regional Orbicare provider network features state-of-the-art medical centers and board-certified specialists in Panama, Spain, Argentina, Turkey, Costa Rica, El Salvador, the Dominican Republic and Colombia.

Physician-founded, Orbicare is distinguished among medical services providers by its expert management team of doctors, employer benefits specialists, and hospital administrators.

Orbicare’s member hospitals provide comprehensive medical care including bariatric and metabolic surgery, dental and orthodontic surgery, oncology, orthopedic and sports medicine, addiction treatment, cosmetic plastic surgery, cardiovascular intervention, and adult stem cell treatment for chronic disease.

Orbicare provides full-service medical benefits programs to individual patients as well as self-ensured employers.

About Medical Travel

The practice of medical travel, or medical tourism, continues to garner considerable attention as a growing number of U.S. employers, consumers and other stakeholders explore cost effective health care options for their organizations.

Experts currently estimate the size of the medical tourism market to reach $100 Billion by 2012. According to HTT CEO Herb Stephens, this increased volume creates a significant issue for international health care providers servicing an international patient base.

A MarketWatch-published Brief by the non-profit National Business Group Health (NGBH) underscores the need for an infrastructure to accommodate the anticipated growth in health travel.

The NGBH identifies innovative and forward-thinking solutions to health care and benefit issues facing large employers, a group that is rapidly adopting medical travel as a key cost-saving solution to growing health care coverage costs.

“The superb level of health care in Orbicare’s provider network throughout Latin America is indisputable," said Stephens. "The question now is how increasing patient volumes can be effectively managed while maintaining high quality service, and keeping the doctor and patient relationship at the center of it all."

About Health Travel Technologies

A technology and services company, HTT operates and licenses the award-winning Inpatra™ platform specifically developed to handle the many demands of health travel – from patient referral through post-op patient follow-up.

”We enable hospitals, physician networks and facilitators like Orbicare to create high-touch, high-efficiency patient management operations,” said HTT Chief Technology Officer Alex Marxer. “Our award-winning patient referral and management application connects the world’s patients and doctors like never before.”

Founded in 2006, and headquartered in San Francisco, California, with operations in San Diego California, Health Travel Technologies, a subsidiary of Health Travel Guides, is a privately held company.

Health Travel Foundation is a non-profit organization dedicated to providing quality care abroad to people who are unable to afford health care procedures or services.

###

Nishant Bagadia
Health Travel Technologies
(415) 651-4395
Email Information

Read the original:
Health Travel Technologies Signs Patient Referral and Management Licensing Partnership with Orbicare Latin American ...

Public release date: 31-Jan-2012
[ | E-mail | Share ]

Contact: Adele Blanchard
ablanchard@cihr.gc.ca
613-946-3308
Canadian Institutes of Health Research

This press release is available in French.

Ottawa, Ontario -- The Harper Government today announced an important investment that will help Canadians in getting more effective treatments and make the healthcare system more sustainable through personalized medicine. The announcement was made by the Honourable Leona Aglukkaq, Minister of Health, and the Honourable Gary Goodyear, Minister of State for Science and Technology.

"Our Government is committed to improving the quality of life of Canadians," Minister Aglukkaq said. "The potential to understand a person's genetic makeup and the specific character of their illness in order to best determine their treatment will significantly improve the quality of life for patients and their families and may show us the way to an improved health care system and even save costs in certain circumstances."

Personalized medicine offers the potential to transform the delivery of healthcare to patients. Healthcare will evolve from a reactive "one-size-fits-all" system towards a system of predictive, preventive, and precision care. Areas in which personalized approaches are particularly promising include oncology, cardiovascular diseases, neurodegenerative diseases, psychiatric disorders, diabetes and obesity, arthritis, pain, and Alzheimer's disease. In all of these fields, and others, a personalized molecular medicine approach is expected to lead to better health outcomes, improved treatments, and reduction in toxicity due to variable or adverse drug responses. For example, cancer patients would be screened to identify those for whom chemotherapy would be ineffective. In addition to saving on the costs of expensive drug treatments, this personalized treatment would prevent a great deal of suffering, while identifying and initiating earlier treatments that would be more effective.

"I applaud Genome Canada and the CIHR for their leadership in supporting research in personalized medicine," said Minister Goodyear. "Innovative approaches like these lead to significant health benefits, enhance our knowledge within the medical arena and can be commercialized to help so many others worldwide."

###

Genome Canada is leading the landmark research competition, with significant collaboration from the Canadian Institutes of Health Research (CIHR) and the Cancer Stem Cell Consortium (CSCC). To qualify for funding, researchers must obtain matching funding that at is least equal to that provided through the competition. Matching funding is typically derived from provincial, academic, private sector or international sources.

Fact Sheet

Further information:

Cailin Rodgers
Office of the Honourable Leona Aglukkaq
Federal Minister of Health
613-957-0200

Stephanie Thomas
Special Assistant (Communications)
Office of the Honourable Gary Goodyear
Minister of State (Science and Technology)
613-960-7728

David Coulombe
Media Relations
Canadian Institutes of Health Research
613-941-4563

Marlene Orton
Director, Media Relations
Genome Canada
613-751-4460 x119
BlackBerry: 613-295-1476

The Canadian Institutes of Health Research (CIHR) is the Government of Canada's health research investment agency. CIHR's mission is to create new scientific knowledge and to enable its translation into improved health, more effective health services and products, and a strengthened Canadian health care system. Composed of 13 Institutes, CIHR provides leadership and support to more than 14,100 health researchers and trainees across Canada. http://www.cihr-irsc.gc.ca

Genome Canada is a non-profit corporation employing an innovative business model based on funding and managing large-scale, multidisciplinary, internationally peer-reviewed genomics research projects in areas such as agriculture, forestry, fisheries, the environment and human health. For more information, visit http://www.genomecanada.ca

The Cancer Stem Cell Consortium is a not-for-profit corporation that was incorporated in 2007 to coordinate an international strategy for cancer stem cell research and related translational activities. For more information, visit http://www.cancerstemcellconsortium.ca

[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

View original post here:
Harper government invests in personalized medicine

The federal government is pledging up to $67.5 million for research into "personalized medicine," which tailors treatment to a patient's genetics and environment.

The funds will flow through Genome Canada, the Cancer Stem Cell Consortium and the Canadian Institutes of Health Research, the federal government's health research agency.

Federal Health Minister Leona Aglukkaq and Minister of State for Science Gary Goodyear made the announcement at the University of Ottawa's health campus Tuesday.

The field of personalized medicine is touted as having the potential to transform the way patients are treated. It looks at the genetic makeup of a person, the patient's environment and the exact course of a particular disease so that an appropriate and effective treatment can be tailored for that individual.

The idea is to move from a one-size-fits-all approach to one that is designed for a specific person and relies on the genetic signatures, or biomarkers, of both the patient and the disease.

Proponents of personalized medicine say it is likely to change the way drugs are developed, how medicines are prescribed and generally how illnesses are managed. They say it will shift the focus in health care from reaction to prevention, improve health outcomes, make drugs safer and mean fewer adverse drug reactions, and reduce costs to health-care systems.

"The potential to understand a person's genetic makeup and the specific character of their illness in order to best determine their treatment will significantly improve the quality of life for patients and their families and may show us the way to an improved health-care system and even save costs in certain circumstances," Aglukkaq said in a news release.

Research projects could last four years

The sequencing of the human genome paved the way for personalized medicine and there have been calls for more research funding so that the discoveries in laboratories can be translated further into the medical field so they will benefit patients more.

Identifying a person's genetic profile, for example, could then indicate a susceptibility to a certain disease, if the biomarkers of that disease have also been discovered. If people know they are genetically at risk of an illness they can take actions to prevent it, and their health-care providers can monitor for it.

Cancer patients could be pre-screened to determine if chemotherapy would work for them, which could not only save a lot of money on expensive treatments but also prevent pain and suffering for patients.

Genome Canada is leading the research initiative, in collaboration with Cancer Stem Cell Consortium and CIHR which on Tuesday launched its Personalized Medicine Signature Initiative. CIHR is committing up to $22.5 million to the large-scale initiative with the other two partners, but it will be providing more funding for other projects under its personalized medicine program.

The research projects are aiming to bring together biomedical, clinical, population health, health economics, ethics and policy researchers to identify areas that are best suited to personalized medicine.

Oncology, cardiovascular diseases, neurodegenerative diseases, psychiatric disorders, diabetes and obesity, arthritis, pain, and Alzheimer’s disease are all considered to be areas that hold promise for personalized medicine.

Funding will also go to projects that are aimed at developing more evidence-based and cost-effective approaches to health care.

Researchers can get up to four years of funding, but 50 per cent of their requested funding must be matched from another source, such as a provincial government or from the academic or private sectors.

Genome Canada, CIHR and the cancer consortium will invest a maximum of $5 million in each individual project.

The successful applicants for the $67.5 million worth of funding won't be announced until December.

The rest is here:
'Personalized medicine' gets $67.5M research boost

Just last week, military brass vowed that the force of the future would be “smaller and leaner.” Apparently, the Army’s taking that pretty damn literally. They want smaller, leaner soldiers. Their best idea to do it? Give GIs transplants of extra fat cells.

Seriously. In the Army’s latest round of small-business research awards, they’ve green-lit a proposal to manufacture transplantable brown fat cells, all in an effort to catalyze rapid weight loss. Portlier soldiers, you might recall, are turning into a major dilemma for top brass. An estimated 75 percent of today’s young Americans are either too fat, too sickly or too dumb to serve. The Army’s even overhauled their fitness program, in part to accommodate softer recruits, by swapping long runs and grueling drills for yoga and calisthenics.

Leg lifts and downward dogs, however, don’t offer much of a calorie-burning boost. Brown fat tissue, however, does. At first glance, the idea of adding fat to get rid of fat doesn’t exactly add up. After all, thousands of Americans dole out mad cash to have flab sucked out, not put back in.

The distinction comes down to varieties of fat: Humans carry pockets of conventional fat, or white adipose tissue. They also carry brown adipose tissue. And recent research has confirmed that the stuff’s pretty damn special: It burns a ton of calories — around 250 calories over three hours in one study group — and actually sucks energy out of conventional fat cells to fuel its fire. Research even suggests that additional pockets of brown fat can be created by exercise.

The Army, however, would rather see soldiers drop pounds like the Real Housewives — with as little effort as possible. They’re funding a team at the University of Boston to “generate human [brown adipose tissue]” for subsequent human transplantation. “Obesity and its associated metabolic complications…are becoming increasingly prevalent in military personnel,” the Army’s research award notes. “Increasing [brown fat] by about 50 grams in obese patients could induce strong weight loss and improve metabolic status.”

Researchers plan to isolate a brown adipose progenitor cell — cells that, similarly to stem cells, are able to differentiate into more specific types — and then generate additional brown adipose cells in the lab. From there, they’d be able to offer “transplantation therapy” to portly personnel.

Of course, plenty of uncertainty about brown fat’s promise still lingers. For one, researchers aren’t sure whether appetite’s increase in conjunction with brown fat stores, keeping weight in stasis. And they don’t know how brown fat affects metabolism and weight loss in the long-term.

But if brown fat really can catalyze weight loss and permanently boost the body’s own metabolic rate, military personnel are hardly the only ones who’d line up for treatment. And civilian companies have already taken note: One Boston company, Ember Therapeutics, recently raised $34 million in capital funding to investigate pharmaceuticals that’d convert white fat to brown.

That said, fat losses aren’t synonymous with fitness gains. In other words, the soldiers of the future might very well be smaller and leaner. But without rigorous exercise, they’ll still, sadly, totally suck at CrossFit.

Photo: Courtesy of Out of Regs

See the article here:
Army’s New Weight-Loss Plan: Transplant Soldiers With Extra Fat

Untreatable conditions can be helped with reprogrammed adult stem cells

In just two years, the celebrated adult stem cell researcher Shinya Yamanaka hopes that clinical trials will begin on curing the once-untreatable spinal injuries with the help of “reprogrammed” adult cells or ‘induced pluripotent stem' (iPS) cells.

Animal trials have shown promising results of transplanting iPS cells to treat paralytic spinal injury, said Professor Yamanaka, delivering a lecture on “New Era of Medicine with iPS Cells” here on Monday.

The lecture was organised as part of the Cell Press-TNQ India Distinguished Lectureship Series.

Prof. Yamanaka, who started his career as a physician 25 years ago and “tried to be an orthopaedic surgeon”, said: “I soon realised I was not so good at surgery. I also realised that even a good surgeon can't help many patients suffering from untreatable diseases and injuries.”

This inspired him to change his career and get back to studying “basic medicine”.

That's where he “met” the iPS cell, which led him to his major scientific breakthrough in 2007 allowing him to “reprogramme” adult human skin cells into embryonic-like stem cells.

The iPS cells have revolutionised research on regenerative medicine: they are free from debates over ethics — often raised in the use of human embryos — and reduce the risk of tissue rejection after transplant. Once established, these cells can be used to elucidate disease mechanisms and to screen drugs.

But creating these cells is both time and money-consuming, he said.

It costs as much as U.S. $ 1 million to treat just one patient, and takes six to eight months to generate, expand and induce differentiation in iPS cells.

“In the case of spinal injuries, we have to transplant the cells within a month after the injury.

“To overcome this, we think it makes sense to create and maintain an iPS cell bank from healthy individuals,” he said.

The risk of rejection by an individual's immune system can be minimised by matching donors with HLA (human leucocyte antigen), a form of “blood type” for human cells.

In Japan, for instance, just 75 unique HLA homozygotes would match 80 per cent of the population, he explained.

Prof. Yamanaka, who was awarded the Albert Lasker Prize in 2009 and the Wolf Prize in 2011, later answered questions from budding biologists and veteran scientists in the audience.

He will speak next in Chennai on February 1 and New Delhi on February 3 as part of the lectureship series.

Here is the original post:
Hopes rise on treating spinal injuries with iPS cells transplant

Public release date: 30-Jan-2012
[ | E-mail | Share ]

Contact: Emily Benson
SRC@faseb.org
301-634-7010
Federation of American Societies for Experimental Biology

Bethesda, MD ? The Federation of American Societies for Experimental Biology (FASEB) announces the opening of registration for the Science Research Conference (SRC): Skeletal Muscle Satellite and Stem Cells.

This conference will take place August 12-17, 2012 in Lucca, Italy. The aim of the conference is to highlight recent advances pertaining to the regulatory mechanisms of myogenic stem cell and progenitor cell populations (such as satellite cells) and their role in growth, regeneration, and therapeutics. This meeting represents the only conference that focuses exclusively on muscle satellite and stem cell populations. Sessions will address: epigenetic and post-transcriptional control of satellite cells, non-myogenic cells in muscle that influence satellite cell biology, biology of satellite cells in the head muscles, satellite cell quiescence, activation and self-renewal, the molecular control of myogenic lineage progression and differentiation, satellite cells in growth and hypertrophy, and satellite cells in aging and disease. Poster sessions will feature these and related topics. Importantly, the participants of this conference will represent interdisciplinary groups that will provide a comprehensive analysis and integration of recent discoveries for the field. The conference will provide collaborative interactions in an attempt to promote future advancements and translational initiatives directed toward the treatment and cure of patients with myopathic diseases.

###

Since 1982, FASEB SRC has offered a continuing series of inter-disciplinary exchanges that are recognized as a valuable complement to the highly successful society meetings. Divided into small groups, scientists from around the world meet intimately and without distractions to explore new approaches to those research areas undergoing rapid scientific changes.

In recent years, the SRC series has expanded into non-summer months. To better enhance the SRC series and allow for future expansion of conferences, FASEB's Office of Scientific Meetings and Conferences recently changed the SRC name from Summer Research Conferences to Science Research Conferences.

FASEB SRC has announced a total of 36 SRCs in 2012, spanning from June through October. To register for an SRC, view preliminary programs, or find a listing of all our 2012 SRCs, please visit http://www.faseb.org/SRC.

Additionally, in efforts to continue expanding the SRC series, potential organizers are encouraged to contact SRC staff at SRC@faseb.org. Proposal guidelines can be found by clicking "Submit a Proposal" on our website at http://www.faseb.org/SRC.

FASEB is composed of 26 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. Celebrating 100 Years of Advancing the Life Sciences in 2012, FASEB is rededicating its efforts to advance health and well-being by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.

[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Read this article:
FASEB SRC Announces Conference Registration Open for: Skeletal Muscle Satellite and Stem Cells

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd.(“ImmunoCellular” or the Company) (OTCBB: IMUC.OB - News), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012. Dr. Singh’s presentation will be titled “Targeting Cancer Stem Cells Via Immunotherapy” and will include an overview of ImmunoCellular’s clinical activities to date including ICT-107, its lead program targeting cancer stem cells (CSC) in Glioblastoma. ICT-107 is currently in a randomized phase II clinical trial at multiple centers in the US. Company is also developing two additional products targeting CSCs in tumors via modulating immune system.

Dr. Singh will also be moderating two of the panel discussions with high level executives from a number of major biotech/pharmaceutical companies. The panel discussions Dr. Singh will be moderating are “Strategic Trends in Immunotherapeutics” at 10:30 am on January 30th and “Investments and Partnership Opportunities in the Immunotherapeutics Space” at 1:30 pm on January 31st.

The Immunotherapeutics Partnering and Deal-making Conference is an immunotherapeutics business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant immunotherapeutics issues and partnerships that will affect the industry. This event also provides a unique venue for attendees to learn about immunotherapeutics business development trends, the market, and novel technologies that shape up the industry.

This conference is also part of the Novel Immunotherapeutics Summit, which consists of this track and three other tracks:

1) 4th Immunotherapeutics and Immunomonitoring

2) 10th Cytokines and Inflammation

3) Allergy Drug Discovery and Development

For more information, please visit www.gtcbio.com

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that the safety and efficacy results obtained in the Phase I trial for the dendritic cell- based vaccine will not be confirmed in subsequent trials; the risk that the correlation between immunological response and progression-free and overall survival in the Phase I trial for ICT-107 will not be reflected in statistically significant larger patient populations; the risk that IMUC will not be able to secure a partner company for development or commercialization of ICT-107. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Read more:
ImmunoCellular Therapeutics To Deliver Presentation on Cancer Stem Cells at Prestigious Immunotherapy Conference

NEWARK, Calif., Jan. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM - News) today announced the publication of preclinical data demonstrating that its proprietary HuCNS-SC(R) cells (purified human neural stem cells) protect host photoreceptors and preserve vision in an animal model of retinal disease. The preclinical results are highly relevant to human disorders of vision loss, the most notable of which is dry age-related macular degeneration (AMD). The study is available online at http://onlinelibrary.wiley.com/doi/10.1111/j.1460-9568.2011.07970.x/abstract and will be featured as the cover article in the February issue of the international peer-reviewed European Journal of Neuroscience.

This research was conducted in collaboration with a team of researchers led by Raymond Lund, Ph.D., Professor Emeritus of Ophthalmology, and Trevor McGill, Ph.D., Research Assistant Professor at the Casey Eye Institute, Oregon Health and Science University.

The results of the study show that photoreceptors, the key cells of the eye involved in vision, were protected from degeneration following transplantation of HuCNS-SC cells into the Royal College of Surgeons (RCS) rat. The RCS rat is a well-established model of retinal disease which has been used extensively to evaluate potential cell therapies. Moreover, the number of cone photoreceptors, which are responsible for central vision, remained constant over an extended period, consistent with the sustained visual acuity and light sensitivity observed in the study. In humans, degeneration of the cone photoreceptors account for the unique pattern of visual loss in dry AMD.

"These results are the most robust shown to date in this animal model," said Dr. Lund, one of the study's lead investigators. "One of the more striking findings is that the effect on vision was long-lasting and correlated with the survival of HuCNS-SC cells more than seven months after transplantation, which is substantially longer than other cell types transplanted into this same model. Also important, particularly for potential clinical application, was that the cells spread from the site of initial application to cover more of the retina over time. These data suggest that HuCNS-SC cells appear to be a well-suited candidate for cell therapy in retinal degenerative conditions."

Alexandra Capela, Ph.D., another of the study's investigators and a senior scientist at StemCells, commented, "This study showed that the HuCNS-SC cells persisted and migrated throughout the retina, with no evidence of abnormal cell formation, which supports our hypothesis of a single transplant therapeutic. With this research, then, we have shown that vision can be positively impacted with a simple approach that does not require replacing photoreceptors or the RPE cells. We look forward to investigating this promising approach in the clinic later this year."

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. Clinical trials are currently underway in spinal cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. In addition, the Company plans to initiate a clinical trial of HuCNS-SC cells in the dry form of age-related macular degeneration in 2012, and is also pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the prospect of the Company's HuCNS-SC cells to preserve vision in animal models of retinal disease; the prospect of successful results from this research collaboration and advancing to clinical testing in age-related macular degeneration or other retinal disease; the potential of the Company's HuCNS-SC cells to treat a broad range of central nervous system disorders; the prospect and timing associated with initiating a clinical trial in a retinal disorder; and the future business operations of the Company, including its ability to conduct clinical trials as well as its other research and product development efforts. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company's HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether the results of the Company's preclinical studies in retinal disease will be replicated in humans; uncertainty as to whether the FDA or other applicable regulatory agencies will permit the Company to continue clinical testing in spinal cord injury, PMD or in future clinical trials of proposed therapies for other diseases or conditions given the novel and unproven nature of the Company's technologies; uncertainties regarding the Company's ability to recruit the patients required to conduct its clinical trials or to obtain meaningful results; uncertainties regarding the Company's ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC and any products that may be generated in the future in the Company's cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; uncertainties regarding the Company's ability to commercialize a therapeutic product and its ability to successfully compete with other products on the market; and other factors that are described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and in its subsequent reports on Forms 10-Q and 8-K.

Go here to read the rest:
StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision

SUNRISE, Fla., Jan. 30, 2012 (GLOBE NEWSWIRE) -- Bioheart (OTCBB:BHRT.OB - News), a leader in developing stem cell therapies to treat cardiovascular diseases, today announced that Frank Young will join Bioheart to be a financial consultant. Young will provide financial oversight of the company's capital fundraising efforts and cultivate relationships within the financial and health care communities to support Bioheart's business goals.

Young previously served as chief financial officer (CFO) with Bioheart from 2003 to 2005. He has more than 30 years' experience launching and managing venture-backed companies in the technology and health care industries.

"Frank's entrepreneurial spirit and successful fundraising strategies, combined with his previous accomplishments at Bioheart, make him an ideal fit for Bioheart," said Mike Tomas, Bioheart's president and CEO. "Frank has a proven track record launching, managing and financially advising numerous companies across the healthcare industry."

Previously Young worked as CFO with CURNA,a health care company known for its discovery of new therapeutic compounds. He engineered the sale of the company in fewer than two years for more than five times the invested capital. He also worked as CFO with Mitral Solutions and Hyperion. As CFO with Bioheart, Young assisted in raising more than $9.5 million from investors in addition to negotiating international manufacturing arrangements and joint ventures.

"I have always been impressed with Bioheart and its success with stem cell research," Young said. "I look forward to becoming an integral part of Bioheart's financial future as it continues to develop life-saving technologies for victims of heart disease."

About Bioheart

Bioheart (OTCBB:BHRT.OB - News) is committed to developing stem cell therapies to treat congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other medical problems. The company focuses on the discovery and development of therapies that will improve patients' quality of life and reduce health care costs and hospitalizations. Bioheart's leading product, MyoCell, is a muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart to improve cardiac function. For more information, visit http://www.bioheartinc.com.

For more information on Bioheart, visit http://www.bioheartinc.com.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.

See original here:
Frank Young Joins Bioheart as Financial Consultant

10-09-2011 19:18 http://www.rhemat.stemtechbiz.com e mail chris@rhemat.co.za The Roll of Stem Cells in your Body Support the Natural Healing System of the Body

Read more from the original source:
Adult Stem Cell Scientist Stem Cell Nutrition Pioneer.flv - Video

05-10-2011 13:45 stemcellremedy.com Stem Cell Remedy User Forum and Blog is a global collaborative effort of regular individuals and trained researchers from organizations across the world focused on helping patients, friends and families, while avoiding the politics associated with other types of research a The sixteenth installment of my original series, "Discovering Religion". In this episode I discuss the current actions of Christian Americans to suppress modern-day scientific advancements. In particular, I address the movement by Christians to outlaw embryonic stem cell, a stance they have no justification from the Bible in taking -- a situation that very closely parallels the Church's suppression of Roger Bacon and Galileo Galilei's scientific discoveries. Additional information I could not include in the video Diabetes: Giving insulin to children with Type I Diabetes is a viable means of treating this disease, however; after 15-20 years of living with type I diabetes, the danger continues to grow, possibly leading to kidney failure, heart disease, blindness, brain damage, and premature death. This is why stem cell research is so crucial to patients suffering from this serious condition. Bone Marrow Transplants: There are many patients, both child and adult, in need of bone marrow transplants that would greatly benefit from the use of stem cells. For 2/3 of them, there is no donor with an acceptable genetic match. However, even when a match is found, it is never perfect. With stem ...

The rest is here:
http://stemcellremedy.com Stem Cell Remedy User Forum

13-01-2012 12:10 http://www.justgiving.com/vanessa-appeal In Feb 2009, Vanessa, then aged 8, was diagnosed with Stage 4 (High-Risk) Neuroblastoma, a very rare, aggressive and difficult to treat form of childhood cancer. Fewer than 100 children in the UK are diagnosed with neuroblastoma each year, most of which are below the age of 5 and generally have a better prognosis as the older the child is the worse the prognosis is. Since Feb 09, Vanessa has undergone many different treatments at Yorkhill Hospital in Glasgow, these include; 12 rounds of High Dose Chemotherapy, two 7 hour surgical operations, the removal of one of her kidneys, a stem cell transplant, Radiotherapy, Retinoic Acid treatment and Immunotherapy treatment......all of which was agonising to watch as parents never mind to have to endure as a child! Having undergone all this difficult and often very painful treatment the fact remained that due to a high relapse rate the long term prognosis for Vanessa's survival remained very poor with less than a 40% survival rate. All the same, Vanessa finished her treatment at Yorkhill Hospital in Aug 2010 and was given the all clear. In Dec 2011 after routine scans, we were given the devastating news that Vanessa had relapsed. She has many hotspots on the skull, neck, spine, leg and knees. The UK doctors have told us that this time round there is very little chance of survival; "much less than 10%" they said, as we do not have any relapse protocols in the UK. This is due to the Government not ...

Go here to read the rest:
Please Help Vanessa - Video

23-01-2012 19:28 "Left this world a little better just because I was here." Yesterday, the 22nd of January, marked a devastating and unforgettable day for all those who knew, loved and followed precious Layla Grace Marsh's story as she battled fiercely against the disease that claimed her life. After a routine check-up following her stem cell transplant Layla's parents were given the news that instead of getting better she had new tumors. Not only were they back in her abdomen but they were now crowding and invading her kidney. Her only good kidney. Precious Layla Grace was sent home with no treatment options aimed toward a cure. She was sent home to pass away. On the 9th of March, 2010 Layla gave up the fight for her "sparky" (sparkly) wings and has been her family's guardian angel ever since. Layla was full of life, happiness, love, fearlessness, determination, spunk, wit, joy and above all, strength. She loved wearing her flower beanies, babylegs and tutus. A smile was always flashed across her cheeky little face and she would often claim that she "had a good day" despite all the shit she was going through at the time. Layla lived, she loved and her legacy on how to do this is still here. I will never forget you. Miss you, boo. This video is dedicated to my wonderful friend through Twitter, Melly. Thank you for motivating me to finish this video even if I had to "cut it off where I finished." Seeing Layla's face and making videos (especially those commemorating certain painful milestones) are ...

Read this article:
january twenty second two thousand ten | two years later. she was here. - Video

28-01-2012 05:25 Warning: Jeunesse Luminesce contains no stem-cells, only stem cell serums, however, below is a blurb that support the use of stem-cells http://www.wisemlm.com http This is a very 'hot button' issue that keeps arising in the face of politicians everywhere in the country. What if anything should the government involve itself in for the issues of stem cell research? How far should the government press into the fields of medical science research? Should the government interfere at all, or stand back and come up with laws to handle the consequences of such research? It comes into question, how many ordinary Americans really know and understand what stem cell research is, how it can effect our lives, and what does it have the ability to do in the future? With topics such as abortion being very hot and causing pressures on all sides, it only seems natural that stem cell research should cause just as much controversy. Many supporters argue that the research gathered will be able to save millions of lives, while those opposing the research all argue that they are killing thousands of innocent children in the process. This brings the question, where do the embryos come from? The majority of the embryos used in the research come from couples that have donated them, following a treatment for infertility; there are often 10 or more embryos left over after such procedures, which can be put to use in the laboratory environment. The options for those embryos are limited; they can be preserved ...

See the article here:
Stem Cells Explained - Jeunesse Luminesce on http://www.WiseMLM.com - Video

Public release date: 27-Jan-2012
[ | E-mail | Share ]

Contact: Daniel Kane
dbkane@ucsd.edu
858-534-3262
University of California - San Diego

Stem cells derived from fat have a surprising trick up their sleeves: Encouraged to develop on a stiff surface, they undergo a remarkable transformation toward becoming mature muscle cells. The new research appears in the journal Biomaterials. The new cells remain intact and fused together even when transferred to an extremely stiff, bone-like surface, which has University of California, San Diego bioengineering professor Adam Engler and colleagues intrigued. These cells, they suggest, could hint at new therapeutic possibilities for muscular dystrophy.

In diseases like muscular dystrophy or a heart attack, "muscle begins to die and undergoes its normal wounding processes," said Engler, a bioengineering professor at the Jacobs School of Engineering at UC San Diego. "This damaged tissue is fundamentally different from a mechanical perspective" than healthy tissue.

Transplanted stem cells might be able to replace and repair diseased muscle, but up to this point the transplants haven't been very successful in muscular dystrophy patients, he noted. The cells tend to clump into hard nodules as they struggle to adapt to their new environment of thickened and damaged tissue.

Engler, postdoctoral scholar Yu Suk Choi and the rest of the team think their fat-derived stem cells might have a better chance for this kind of therapy, since the cells seem to thrive on a stiff and unyielding surface that mimics the damaged tissue found in people with MD.

In their study in the journal Biomaterials, the researchers compared the development of bone marrow stem cells and fat-derived stem cells grown on surfaces of varying stiffness, ranging from the softness of brain tissue to the hardness of bone.

Cells from the fat lineage were 40 to 50 times better than their bone marrow counterparts at displaying the proper proteins involved in becoming muscle. These proteins are also more likely to "turn on" in the correct sequence in the fat-derived cells, Engler said.

Subtle differences in how these two types of cells interact with their environment are critical to their development, the scientists suggest. The fat-derived cells seem to sense their "niche" on the surfaces more completely and quickly than marrow-derived cells. "They are actively feeling their environment soon, which allows them to interpret the signals from the interaction of cell and environment that guide development," Choi explained.

Perhaps most surprisingly, muscle cells grown from the fat stem cells fused together, forming myotubes to a degree never previously observed. Myotubes are a critical step in muscle development, and it's a step forward that Engler and colleagues hadn't seen before in the lab.

The fused cells stayed fused when they were transferred to a very stiff surface. "These programmed cells are mature enough so that they don't respond the environmental cues" in the new environment that might cause them to split apart, Engler says.

Engler and colleagues will now test how these new fused cells perform in mice with a version of muscular dystrophy. The cells survive in an environment of stiff tissue, but Engler cautions that there are other aspects of diseased tissue such as its shape and chemical composition to consider. "From the perspective of translating this into a clinically viable therapy, we want to know what components of the environment provide the most important cues for these cells," he said.

###

Co-authors for the Biomaterials study "Mechanical derivation of functional myotubes from adipose-derived stem cells" include Ludovic G. Vincent and Andrew R. Lee in the Department of Bioengineering at the UC San Diego Jacobs School of Engineering, and Marek K. Dobke from the Division of Plastic Surgery, UC San Diego School of Medicine. The research was funded by the Human Frontier Science Program and the National Institutes of Health Common Fund.

[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

See the original post:
Need muscle for a tough spot? Turn to fat stem cells, UC San Diego researchers say

To: HEALTH, MEDICAL AND NATIONAL EDITORS

CLEVELAND, Jan. 30, 2012 /PRNewswire-USNewswire/ -- Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow. Juventas recently presented the 12-month results from its Phase I heart failure trial at the 7th International Conference on Cell Therapy for Cardiovascular Disease.

(Logo: http://photos.prnewswire.com/prnh/20120130/DC43104LOGO)

The 17-person, open-label, dose-escalation study targeted New York Heart Association (NYHA) class III heart failure patients, who represent approximately a quarter of the 6 million heart failure patients in the United States and account for half of all heart failure hospital admissions. The clinical trial met its primary safety endpoint with no serious adverse events deemed drug related. Fifteen of the 17 patients survived to a year. Importantly, patients receiving target therapeutic doses demonstrated clinically significant improvements at 12 months in 6 minute walk distance (6MWD) and the Minnesota Living with Heart Failure Questionnaire (MLHFQ). Nearly half of the patients improved a full NYHA class, with multiple patients improving 2 full classes.

"The patient population we treated in this trial have a true unmet clinical need and tend to have rapidly deteriorating quality of life," states Marc Penn, M.D., Ph.D, Founder and Chief Medical Officer for Juventas and Director of Cardiovascular Research at the Summa Cardiovascular Institute at Summa Health System. "To see clinical symptomatic benefits of this magnitude maintained from 4 to 12 months after JVS-100 treatment suggests we are inducing fundamental changes in the heart of treated patients. We believe this is consistent with our understanding of the mechanisms associated with JVS-100 and warrants further investigation."

Based on these results, the company is preparing to enroll a placebo-controlled, randomized, double blinded Phase II heart failure clinical trial in the United States to further define the efficacy of JVS-100. Also, Juventas has received FDA clearance to enroll a Phase IIa trial evaluating safety and efficacy of JVS-100 in patients with critical limb ischemia. The CLI trial is enrolling patients in the United States and India. In addition to safety, the trial will assess time to amputation and other efficacy endpoints and will begin enrollment in the first quarter of 2012.

"We are thrilled by our Phase I data and excited to be transitioning into multiple mid-stage clinical trials," states Rahul Aras, Ph.D., President and CEO for Juventas. "We are excited about the platform potential for JVS-100 in a broad range of clinical indications."

About Juventas Therapeutics

Juventas Therapeutics, headquartered in Cleveland, OH, is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life-threatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials. Investors include New Science Ventures, Takeda Ventures, Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received non-dilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.

About JVS-100

The company's lead product, JVS-100 encodes Stromal-cell Derived Factor 1 (SDF-1). SDF-1 promotes tissue repair through recruitment of endogenous stem cells to the damaged organ, promotion of new blood vessel formation and prevention of ongoing cell death. The SDF-1 repair pathway is well-conserved in a broad range of end organ systems, including the heart, vasculature, dermis, kidney, and eye. JVS-100 is currently being clinically evaluated for treatment of heart failure and late stage peripheral vascular disease and has been shown to protect and repair tissue following organ-damage in a broad range of pre-clinical disease models.

SOURCE Juventas Therapeutics

-0-

See more here:
Juventas Therapeutics Reports One Year Data From Phase I Heart Failure Clinical Trial

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology,
Inc. (“ACT”;
OTCBB: ACTC), a leader in the field of regenerative
medicine, announced today that the Aberdeen Royal Infirmary,
the largest of the Grampian University Hospitals in Scotland,
has been confirmed as a site for its Phase 1/2 human clinical
trial for Stargardt’s Macular Dystrophy (SMD) using retinal
pigment epithelial (RPE) cells derived from human embryonic
stem cells (hESCs). The Phase 1/2 trial is a prospective,
open-label study designed to determine the safety and
tolerability of the RPE cells following sub-retinal
transplantation into patients with SMD.

“A leading medical institution in the United Kingdom, Aberdeen
Royal Infirmary is an ideal partner for our European clinical
trial for SMD,” said Gary Rabin, chairman and CEO of ACT.
“Moreover, we are particularly pleased that the lead
investigator is Dr. Noemi Lois, a leading expert in SMD. We
continue to forge ties with some of the best eye surgeons and
hospitals in the world and work towards bringing this
cutting-edge therapy closer to fruition. Our preliminary
results to date keep us optimistic that we are on the right
path both in terms of our science and the clinical team we are
working with, particularly eye surgeons such as Dr. Lois.”

Stargardt's Macular Dystrophy affects an estimated 80,000 to
100,000 patients in the U.S. and Europe, and causes progressive
vision loss, usually starting in people between the ages of 10
to 20, although the disease onset can occur at any age.
Eventually, blindness results from photoreceptor loss
associated with degeneration in the pigmented layer of the
retina, the retinal pigment epithelium. “The first Stargardt’s
patient to be treated in the U.S. with stem cell-derived RPE
cells was a patient who was already legally blind as a
consequence of this disease” stated Dr. Robert Lanza M.D., the
chief scientific officer at ACT. Preliminary results from the
treatment of the first SMD patient were recently
reported in
The Lancet (23 January 2012) and have been
characterized by experts in the field of regenerative medicine
as providing early signs of safety and efficacy.

This approved SMD clinical trial that Dr. Lois and her team
will participate in is a prospective, open-label study designed
to determine the safety and tolerability of RPE cells derived
from hESCs following sub-retinal transplantation to patients
with advanced SMD, and is similar in design to the FDA-cleared
US trial initiated in July 2011.

“It is an honor to have been designated as a site for this
path-breaking clinical trial,” said Noemi Lois, M.D., Ph.D. “We
could not be more pleased to be a part of this trial for a
promising potential new treatment for SMD, using hESC-derived
RPE cells.” Dr. Lois is a is a member of the Department of
Ophthalmology, NHS Grampian, and associated to the University
of Aberdeen, Scotland, United Kingdom. Dr. Lois practices at
the Aberdeen Royal Infirmary; she is an Ophthalmologist with
special interest in Medical retina and Retinal surgery.

On January 23, 2012, the company
announced that the first patient in this SMD clinical trial
in Europe had been treated at Moorfields Eye Hospital in
London.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company
applying cellular technology in the field of regenerative
medicine. For more information, visit
http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial
and operating results, future growth in research and
development programs, potential applications of our technology,
opportunities for the company and any other statements about
the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform
Act of 1995. Any statements that are not statements of
historical fact (including statements containing the words
“will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered
to be forward-looking statements. There are a number of
important factors that could cause actual results or events to
differ materially from those indicated by such forward-looking
statements, including: limited operating history, need for
future capital, risks inherent in the development and
commercialization of potential products, protection of our
intellectual property, and economic conditions generally.
Additional information on potential factors that could affect
our results and other risks and uncertainties are detailed from
time to time in the company’s periodic reports, including the
report on Form 10-K for the year ended December 31, 2010.
Forward-looking statements are based on the beliefs,
opinions, and expectations of the company’s management at the
time they are made, and the company does not assume any
obligation to update its forward-looking statements if those
beliefs, opinions, expectations, or other circumstances should
change. Forward-looking statements are based on the beliefs,
opinions, and expectations of the company’s management at the
time they are made, and the company does not assume any
obligation to update its forward-looking statements if those
beliefs, opinions, expectations, or other circumstances should
change. There can be no assurance that the Company’s clinical
trials will be successful.

See the rest here:
ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived ...

NEW YORK, Jan. 30, 2012 /PRNewswire/ -- Reportlinker.com
announces that a new market research report is available in its
catalogue:

Biobanking for Medicine: Technology and Market
2012-2022

http://www.reportlinker.com/p0765582/Biobanking-for-Medicine-Technology-and-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

Report Details

What does the future hold for biobanks? Visiongain's report
shows you potential revenues and trends to 2022. Find data,
forecasts and discussions for biobanking in medicine.

Discover sales predictions at overall market, submarket and
national levels to 2022. Our study gives you business research,
analysis and opinion for applications in medical research,
pharmaceuticals and diagnostics. 

How will the biobanking industry perform? Receive forecasts for
human tissue banking, stem cell banking, private cord banking,
other services (e.g., DNA and RNA storage), commercial
biobanks, academic collections and other operations. You find
revenues and discussions.

R&D applications are multiplying and widening. Assess
contributions of biobanks in understanding disease, drug
discovery, drug development and biomarkers. This decade will
result in technological and organisational progress, public and
private, benefiting healthcare. 

Our report discusses Cryo-Cell International, Cord Blood
America, Tissue Solutions, Asterand,
ViaCord, LifebankUSA, China Cord Blood and other
organisations. See activities and outlooks. 

Biobanks and biorepositories will become more important to
medical R&D and human healthcare. Biological science and
technology stand to benefit. Discover the prospects. 

Visiongain's study provides data, analysis and opinion aiming
to help your research, calculations, meetings and
presentations. You can find answers now in our work.

Revenue forecasts, market shares, developmental trends,
discussions and interviews

In the report you find revenue forecasting, growth rates,
market shares, qualitative analyses (incl. SWOT and STEP), news
and views. You receive 72 tables and charts and six research
interviews.

Advantages of Biobanking for Medicine: Technology and
Market 2012-2022 for your work

In particular, this study gives you the following knowledge and
benefits:• Find revenue predictions to 2022 for the overall
world market and submarkets, seeing growth trends• Assess
companies in medical biobanking, discovering activities and
outlooks• See revenue forecasts to 2022 in leading countries
for human tissue banking -
US, Japan, Germany,France, UK, Spain, Italy, China and India•
Review developmental trends for biobanks - technologies and
services• Investigate competition and opportunities influencing
commercial results• Find out what will stimulate and restrain
that industry and market• View expert opinions from our survey
of that biotechnology sector.

There, you receive a distinctive mix of quantitative and
qualitative work with independent predictions. We analyse
developments and prospects, helping you to stay ahead.

Gain business research, data and analysis for medical
biobanking Our study is for everybody needing industry
and market analyses for medical biobanks. Find data, trends and
answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal
GovernmentCCR Ref number: KD4R6 

Table of Contents1. Executive Summary

1.1 Summary Points of this Report

1.2 Aims, Scope and Format of the Report

1.2.1 Speculative Aspects of Assessing the Biobanking Market

1.2.2 Chapter Outlines

1.3 Research and Analysis Methods

1.3.1 Human Tissue Banking Market

1.3.2 Stem Cell Banking Market

2. Introduction to Biobanking2.1 Biobanking2.1.1 Processes
Involved in Biobanking2.2 Biobanks: A Two-Fold Character2.3 Key
Features2.4 Classification of Biobanks2.4.1 Volunteer
Groups2.4.1.1 Population-Based Biobanks2.4.1.2 Disease-Oriented
Biobanks2.4.2 Ownership or Funding Structure2.5 Guidelines and
Standards2.5.1 Guidelines for Biobanks and Use of Biological
Samples for Research2.5.2 Industry Standards for Biobanks2.5.3
Biobanking Processes Governed by Guidelines2.6 Laws and
Regulations for Biobank-Based Research

3. Biobanking and the Pharmaceutical Industry

3.1 Scientific and Commercial Use of Biobanking in the
Pharmaceutical Industry

3.1.1 Research and Drug Development

3.1.1.1 Understanding Disease Pathways

3.1.1.2 Drug Discovery

3.1.1.3 Biomarker Discovery

3.1.2 Therapeutics

3.1.3 Clinical Trials

3.2 Biobanks Operated by Pharmaceutical Companies

4. Biobanking Associated Market: Systems, Software, Consumables
and Services Associated with Biobanking4.1 Overview4.2
Systems/Technologies4.2.1 Automated Liquid Handling4.2.1.1
Frozen Aliquotting: New Technology in Development4.2.2
Storage4.2.2.1 Ultra-Low Temperature Freezing4.2.2.2
Room-Temperature Storage4.2.3 RFID and Tagging Technologies4.3
Software4.3.1 Laboratory Information Management System
(LIMS)4.3.1.1 LIMS Functions4.4 Consumables4.5 Services

5. The World Medical Biobanking Market to 2022

5.1 Current State of the Biobanking Market

5.2 Geographical Footprint

5.3 Growing Demand for Biobank Resources

5.4 Revenue Forecast for Overall Market

5.4.1 Scope and Limitations

5.4.2 Biobanking Market, 2011-2022

5.4.2.1 Sales Forecasts for Biobanking Market, 2011-2016

5.4.2.2 Sales Forecasts for Biobanking Market, 2017-2022

5.5 Commercial Biobanks: New Resources for Research

6. Human Tissue Banking Market6.1 Revenue Forecast for Overall
Human Tissue Banking Market, 2011-20226.1.1 Revenue Forecast
for Overall Human Tissue Banking Market, 2011-20166.1.2 Revenue
Forecast for Overall Human Tissue Banking Market, 2017-20226.2
Revenue Forecasts for Human Tissue Banking Market by Type of
Biobank, 2011-20226.2.1 Revenue Forecast for Commercial Human
Tissue Banking Market, 2011-20166.2.2 Revenue Forecast for
Commercial Human Tissue Banking Market, 2017-20226.2.3 Revenue
Forecast for Academic & Other Human Tissue Banking Market,
2011-20166.2.4 Revenue Forecast for Academic & Other Human
Tissue Banking Market, 2017-20226.3 Revenue Forecasts for Human
Tissue Banking in Leading National Markets, 2011-20226.4 Some
Commercial Participants in the Human Tissue Banking Market6.4.1
Business Models of Companies in the Biobanking Market6.4.2
Tissue Solutions6.4.2.1 Overview6.4.2.2 Global Presence6.4.2.3
Products and Services6.4.2.3.1 Banked Samples6.4.2.3.2
Prospective Samples6.4.2.3.3 Fresh Samples6.4.2.3.4 Freshly
Isolated and Primary Cells6.4.2.3.5 Services6.4.2.4 Strengths
and Capabilities6.4.2.5 Future Outlook6.4.3 Asterand6.4.3.1
Overview6.4.3.2 Global Presence6.4.3.3 Products and
Services6.4.3.3.1 XpressBANK6.4.3.3.2 ProCURE6.4.3.3.3
PhaseZERO6.4.3.3.4 BioMAP6.4.3.4 Asterand: Raised Barriers for
New Market Entrants?6.4.3.5 Financial Performance6.4.3.6 Future
Outlook

7. Stem Cell Banking

7.1 Overview

7.2 Revenue Forecast for Overall Stem Cell Banking Market,
2011-2022

7.2.1 Revenue Forecast for Stem Cell Banking Market, 2011-2016

7.2.2 Revenue Forecast for Stem Cell Banking Market, 2017-2022

7.3 Stem Cell Banks for Research: High Growth Possible

7.4 Umbilical Cord Blood Banking for Stem Cells

7.4.1 Blood Banks: Private vs. Public

7.4.2 Biological Insurance: Private Blood Banking

7.4.3 Umbilical Cord Banking: The Controversies

7.4.3.1 US Oversight of Cord Blood Stem Cells

7.4.4 Revenue Forecast for Private Cord Blood Banking Market,
2011-2016

7.4.5 Revenue Forecast for Private Cord Blood Banking Market,
2017-2022

7.4.6 Companies in the Field

7.4.6.1 Cord Blood America: Looking Towards the Chinese
Market

7.4.6.2 ViaCord: 145,000 Blood Units in Storage

7.4.6.3 Cryo-Cell International: The First Cord Blood Bank

7.4.6.4 Stem Cell Authority: Exclusive Stem Cells

7.4.6.5 LifebankUSA: Placenta-Cord Banking

7.4.6.6 Biogenea-Cellgenea

7.4.6.7 China Cord Blood Corp

7.4.6.8 Cryo-Save

7.4.6.9 Thermogenesis

7.5 Gene/DNA Banking

8. Industry Trends8.1 Automated Biobanking8.1.1 Increased
Uptake of Laboratory Information Management Systems (LIMS) in
Biobanking8.1.2 Addressing Sample Storage and Tracking
Issues8.2 Green Banking8.3 Creation of National Biobanks8.4
HIPAA Amendments

9. Qualitative Analysis of the Biobanking Sector

9.1 Strengths

9.1.1 Wealth of Information for Genetic Research

9.1.2 Potential to Change Treatments

9.1.3 Many Governments Support Biobanking

9.2 Weaknesses

9.2.1 Quality Concerns for Some Existing Biospecimen
Collections

9.2.2 Lack of Standardisation and Harmonisation of Best
Practices

9.2.3 Limited Sharing and Linkage of Biobanks

9.3 Opportunities

9.3.1 Genome-Wide Association Studies (GWAS)

9.3.2 Personalised Medicine

9.3.3 Pharmacogenomics: Driving the Personalised Medicine
Approach

9.4 Threats

9.4.1 Ethical and Regulatory Issues

9.4.1.1 Limitations of Informed Consent in Biobanking

9.4.1.2 Confidentiality and Security to Prevent Improper Use

9.4.2 Social and Cultural Issues

9.4.3 Ownership Issues

9.4.4 Funding

10. Research Interviews from Our Survey10.1 Dr Morag McFarlane,
Chief Scientific Officer, Tissue Solutions10.1.1 On the Use of
Biobank Samples in the Pharmaceutical Industry 10.1.2 On
Commercial Aspects of Biobanking10.1.3 On the Business of
Tissue Solutions10.1.4 On the Attractiveness of Human Tissue
Banking10.1.5 On the Future of the Biobanking Market10.2 Dr
Angel García Martín, Director, Inbiomed10.2.1 On the Importance
of Biobanking in the Pharmaceutical Industry 10.2.2 On the
Use of Technology in Biobanking 10.2.3 On Increased
Recognition of Biobanking and Harmonisation of
Samples 10.2.4 On the Use of Biobanks by the
Pharmaceutical Industry 10.2.5 On Private Biobanks and
Scale of Operations 10.2.6 On Commercial and Public
Biobanking and Legislation 10.2.7 On the Most Attractive
Segment in Commercial Biobanking10.2.8 On the Future of
Biobanking: Drivers and Challenges10.3 Dr Piet Smet, Director,
Business Development, BioStorage Technologies10.3.1 On Defining
Biorepositories and Biobanks10.3.2 On the Services of
Biostorage10.3.3 On Main Customers for Biostorage10.3.4 On the
Importance of Biorepositories in Research and Industry10.3.5 On
Technology Use in Biobanks10.3.6 On Increased Recognition of
Biobanking and Harmonisation of Samples 10.3.7 On the Use
of Biobanks by the Pharmaceutical Industry 10.3.8 On
Private Biobanks and Scale of Operations 10.3.9 On
Commercial and Public Biobanking and Legislation 10.3.10
On the Most Attractive Segment in Commercial Biobanking10.3.11
On Biobanking in 202010.3.12 On Drivers and Challenges in the
Sector10.4 Dr Tom Hoksbergen, Marketing and Sales,
SampleNavigator Laboratory Automation Systems10.4.1 On the
Services of SampleNavigator10.4.2 On Main Customers for
SampleNavigator10.4.3 On the Importance of Biorepositories in
Research and Industry10.4.4 On Technology Use in Biobanks10.4.5
On Increased Recognition of Biobanking and Harmonisation of
Samples 10.4.6 On the Use of Biobanks by the
Pharmaceutical Industry 10.4.7 On Commercial
Biorepositories/Banks and Scale of Operations 10.4.8 On
Commercial and Public Biobanking10.4.9 On the Most Attractive
Segment in Commercial Biobanking10.4.10 On Biobanking in
202010.4.11 On Drivers and Challenges in the Sector10.5 Mr Rob
Fannon, Clinical Operations Manager, BioServe10.5.1 On the
Services of BioServe10.5.2 On Main Customers for BioServe10.5.3
On the Importance of Biorepositories in Research and
Industry10.5.4 On Technology Use in Biobanks10.5.5 On Increased
Recognition of Biobanking and Harmonisation of
Samples 10.5.6 On the Use of Biobanks by the
Pharmaceutical Industry 10.5.7 On Commercial
Biorepositories/Banks and Scale of Operations 10.5.8 On
Commercial and Public Biobanking10.5.9 On the Most Attractive
Segment in Commercial Biobanking10.5.10 On Biobanking in
202010.5.11 On Drivers and Challenges in the Sector10.6 Dr
Frans A.L. van der Horst, Chairman, Dutch Collaborative
Biobank10.6.1 On Importance of Biorepositories in Research and
Industry10.6.2 On Increased Recognition of Biobanking and
Harmonisation of Samples 10.6.3 On the Services of Dutch
Collaborative Biobank10.6.4 On Commercial Drivers for
Bio-Repositories/Biobanking Market10.6.5 On Commercial and
Public Biobanking10.6.6 On Sustaining/Recovering Costs10.6.7 On
the Most Attractive Segment in Commercial Biobanking10.6.8 On
Ethical, Legal and Social Issues in Biorepositories/Biobanks

11. Conclusions

11.1 Biobanking for Research and Therapeutics

11.2 Biobanking: The Future for Drug Discovery and Personalised
Medicine

11.3 Commercial Drivers of the Biobanking Market

11.4 The Sector Has Marked Challenges, but Many Opportunities
for Growth

List of TablesTable 2.1 Prominent Population-Based
Biobanks, 2011

Table 2.2 Prominent Disease-Oriented Biobanks, 2011

Table 2.3 Some Guidelines and Recommendations for Biobanks,
2011

Table 2.4 Laws and Regulations for Biobank-Based Research,
Consent Requirements, and Privacy/ Data Protection, 2011

Table 3.1 Some Pharmaceutical and Biotechnology Companies with
In-House Biobanks, 2011

Table 4.1 Prominent Companies in the Automated Liquid Handling
Market, 2011

Table 4.2 Prominent Companies in Ultra-Low Temperature Freezer
Market, 2011

Table 4.3 Prominent LIMS Vendors, 2011

Table 4.4 Prominent Consumables Suppliers for Biobanking, 2011

Table 4.5 Prominent Biorepository Service Providers, 2011

Table 5.1 Estimated Number of Biobanks in Europe, 2011

Table 5.2 Biobanking Market: Grouped Revenue Forecasts,
2010-2016

Table 5.3 Biobanking Market: Grouped Revenue Forecasts,
2017-2022

Table 6.1 Human Tissue Banking Market: Overall Revenue
Forecast, 2010-2016

Table 6.2 Human Tissue Banking Market: Overall Revenue
Forecast, 2017-2022

Table 6.3 Human Tissue Banking Market: Revenue Forecasts by
Type of Biobank, 2010-2016

Table 6.4 Human Tissue Banking Market: Revenue Forecasts by
Type of Biobank, 2017-2022

Table 6.5 Human Tissue Banking Market: Revenue Forecasts for
Leading National Markets, 2010-2016

Table 6.6 Human Tissue Banking Market: Revenue Forecasts for
Leading National Markets, 2017-2022

Table 6.7 Some Leading Companies in the World Biobanking
Market, 2011

Table 6.8 Asterand: Revenue by Segment, 2009 and 2010

Table 6.9 Asterand: Revenue by Geographical Area, 2010

Table 7.1 Stem Cell Banking Market: Overall Revenue Forecast,
2010-2016

Table 7.2 Stem Cell Banking Market: Overall Revenue Forecast,
2017-2022

Table 7.3 Prominent Stem Cell Banks Serving the Research
Community, 2011

Table 7.4 Costs of Various Private Cord Blood Banks Worldwide,
2011

Table 7.5 Private Cord Blood Banking Market: Revenue Forecast,
2010-2016

Table 7.6 Private Cord Blood Banking Market: Revenue Forecast,
2017-2022

Table 7.7 Cord Blood Banking Market: Drivers and Restraints,
2012-2022

Table 7.8 Some Prominent Companies in the Cord Blood Banking
Market, 2011

Table 7.9 Cryo-Cell International Revenue, 2009-2010

Table 7.10 China Cord Blood Corp Revenue and Subscribers,
2009-2010

Table 7.11 Cryo-Save Revenue and Operating Profit, 2009-2010

Table 7.12 Cryo-Save Revenue by Region, 2010

Table 9.1 SWOT Analysis of the Biobanking Market: Strengths and
Weaknesses, 2012-2022

Table 9.2 SWOT Analysis of the Biobanking Market: Opportunities
and Threats, 2012-2022

Table 9.3 Information for a Biobank Donor, 2011

Table 11.1 Human Tissue Biobanking Market by Country, 2010,
2016, 2019 & 2022

List of FiguresFigure 2.1 Main Processes Involved in
Biobanking, 2011

Figure 2.2 Classification of Biobanks, 2011

Figure 3.1 Biobanking and Pharmaceutical Development, 2011

Figure 4.1 Biobanking, Applications and Users, 2011

Figure 4.2 Functions of LIMS, 2011

Figure 5.1 Overall Biobanking Market: Revenue Forecast,
2010-2016

Figure 5.2 Overall Biobanking Market: Revenue Forecast,
2017-2022

Figure 6.1 Human Tissue Banking Market: Overall Revenue
Forecast, 2010-2016

Figure 6.2 Human Tissue Banking Market: Overall Revenue
Forecast, 2017-2022

Figure 6.3 Human Tissue Banking Market: Forecast by Type of
Biobank, 2010-2016

Figure 6.4 Human Tissue Banking Market: Forecast by Type of
Biobank, 2017-2022

Figure 6.5 Human Tissue Banking Market: Share by Type of
Biobank, 2010

Figure 6.6 Human Tissue Banking Market: Share by Type of
Biobank, 2022

Figure 6.7 World and US Human Tissue Banking Markets: Revenue
Forecasts, 2010-2022

Figure 6.8 Japan, EU 5 and Other Leading Human Tissue
Banking Markets: National Revenue Forecasts, 2010-2022

Figure 6.9 Human Tissue Banking: National Market Shares, 2010

Figure 6.10 Human Tissue Banking: National Market Shares, 2016

Figure 6.11 Human Tissue Banking: National Market Shares, 2019

Figure 6.12 Human Tissue Banking: National Market Shares, 2022

Figure 6.13 Commercial Sourcing of Biological Samples, 2011

Figure 6.14 Commercial Banking of Biological Samples, 2011

Figure 6.15 Asterand: Revenues, 2009 & 2010

Figure 6.16 Asterand: Revenue Shares by Region of Destination,
2010

Figure 6.17 Asterand: Revenue Shares by Region of Origin, 2010

Figure 7.1 Stem Cell Banking Market: Revenue Forecast,
2010-2016

Figure 7.2 Stem Cell Banking Market: Revenue Forecast,
2017-2022

Figure 7.3 Twenty-Year Storage Costs at Various Private Cord
Blood Banks Worldwide, 2011

Figure 7.4 Cord Blood Banking Market: Revenue Forecast,
2010-2016

Figure 7.5 Cord Blood Banking Market: Revenue Forecast,
2017-2022

Figure 7.6 Cryo-Cell International Revenue, 2009-2010

Figure 7.7 China Cord Blood Corp Revenue and Subscribers,
2009-2010

Figure 7.8 Cryo-Save Revenue and Operating Profit, 2009-2010

Figure 7.9 Cryo-Save Revenue Shares by Region, 2010

Figure 11.1 Biobanking Market: World Sales Forecast, 2010,
2012, 2016, 2019 & 2022 

Companies ListedAbcellute

Abgene

Adnexus Therapeutics

AFNOR Groupe

AKH Biobank

AlloSource

American National Bioethics Advisory Commission 

American Type Culture Collection

Amgen

Analytical Biological Services

ARCH Venture Partners

Asterand

AstraZeneca

Australasian Biospecimen Network (ABN)

Autoscribe

AXM Pharma 

Bayer-Schering

Beckman Coulter

Beike Biotechnology 

Biobank Ireland Trust

Biobank Japan

Biobanking and Biomolecular Resources Research Infrastructure
(BBMRI) 

BioFortis

Biogen Idec

Biogenea-CellGenea 

BioLife Solutions

Biomatrica

Biopta

BioRep

BioSeek

BioServe

BioStorage LLC

BioStorage Technologies

BrainNet Europe

Caliper LifeSciences

Canadian Partnership for Tomorrow

CARTaGENE

Cellgene Corporation

Cells4Health

Chemagen

China Cord Blood Corp

Chinese Ministry of Health

CLB/Amsterdam Medical Center

CorCell

Cord Blood America

Cord Blood Registry 

CORD:USE (US Public Cord Blood Bank) 

CordLife

Cordon Vital (CBR) 

Coriell Institute for Medical Research

Council of Europe (CoE)

Covance

Cryo Bio System

Cryo-Cell International

Cryometrix

Cryo-Save

Cureline

Cybrdi

Danubian Biobank Foundation

deCODE Genetics

Department of Health (DoH, UK)

Draper Laboratory

Duke University Medical Center

Dutch Collaborative Biobank

EGeen

Eli Lilly

Eolas Biosciences 

Estonian Genome Project

EuroBioBank

European Commission (EC)

European Health Risk Monitoring (EHRM)

European Medicines Agency (EMA/EMEA)

European Union Group on Ethics (EGE)

Fisher BioServices

Fondazione I.R.C.C.S. Istituto Neurologico C. Besta

Food and Drug Administration (US FDA)

Foundation for the National Institutes of Health 

Fundación Istituto Valenciano de Oncología

Fundeni Clinical Institute

Genentech

Generation Scotland

GeneSaver

GeneSys

Genetic Association Information Network (GAIN)

Genizon Biosciences

Genome Quebec Biobank 

GenomEUtwin

Genomic Studies of Latvian Population

GenVault

German Dementia Competence Network

GlaxoSmithKline (GSK)

H. Lee Moffitt Cancer Center and
Research Institute 

Hamilton

Hopital Necker Paris - Necker DNA Bank

Human Tissue Authority (HTA)

Hungarian Biobank

HUNT, Norway

ILSBio LLC

Inbiobank

Inbiomed

Indivumed

INMEGEN

Institut National de la Santé et de la Recherche Médicale
(INSERM)

Integrated BioBank of Luxembourg

International Agency for Research on Cancer (IARC)

International Air Transport Association (IATA)

International Organization for Standardization (ISO)

International Society for Biological and Environmental
Repositories (ISBER)

International Stem Cell Corporation

Kaiser Permanente

KORA-gen

LabVantage Solutions

LabWare

Leiden University Medical Center

LifebankUSA

LifeGene

LifeStem

Malaysian Cohort Project

Matrical Biosciences

Matrix

Medical Research Council (MRC)

Medical University of Gdansk

Merck & Co.

Merck Sharp & Dohme Limited (MSD)

Merck-Serono

Micronic

Millennium (Takeda Oncology Company)

MVE-Chart

National Cancer Institute (NCI)

National DNA Bank (US)

National Human Genome Research Institute (NHGRI)

National Institute of Environmental Health

National Institutes of Health (NIH)

National Public Health Institute 

National Research Ethics Service (NRES) 

NeoCodex

NeoStem

Neuromuscular Bank of Tissues and DNA Samples

New Brunswick Scientific

NEXUS Biosystems

Northwest Regional Development Agency

Novacare Bio-Logistics

Novartis

NUgene Project

Ocimum Biosolutions

Office of Biorepositories and Biospecimen Research (OBBR)

OnCore UK

Organisation for Economic Co-operation and Development (OECD)

OriGene

Oxagen

Pacific Bio-Material Management

PathServe

Perkin Elmer

Pfizer

Pharmagene Laboratories Trustees Limited

Polaris Ventures 

Pop-Gen (University Hospital Schleswig-Holstein)

PrecisionMed

Prevention Genetics

ProMedDx

Promoting Harmonisation of Epidemiological Biobanks
in Europe (PHOEBE)

ProteoGenex

Public Population Projects in Genomics (P3G Consortium)

Qiagen

RAND Corporation

Regenetech

REMP

Reproductive Genetics Institute (RGI)

Research Centre of Vascular
Diseases, University of Milan

Rhode Island BioBank, Brown University

Roche

RTS Life Science

Saga Investments LLC

SampleNavigator Laboratory Automation Systems

Sanofi

SANYO Biomedical

Scottish Government

Seattle Genetics

Sejtbank (Hungarian Cord Blood Bank) 

SeqWright DNA Technology Services

SeraCare Life Sciences

Singapore Tissue Network

StarLIMS

Steelgate

Stem Cell Authority

Stem Cells for Safer Medicine (SC4SM)

Stem Cells Research Forum of India

Stemride International

Taiwan Biobank

Taizhou Biobank

TAP

Tecan

The Automation Partnership

The Sorenson Molecular Genealogy Foundation (SMGF)

Thermo Fisher Scientific

Thermogenesis

Tissue Bank Cryo Center (Bulgaria)

Tissue Solutions

Titan Pharmaceuticals

TotipotentSC

Trinity Biobank

Tumorothèque Necker-Entants Malades

UK Biobank

UK Stem Cell Bank

UmanGenomics

Umeå University

University Hospital Angers

University Medical Center Gent

University of Massachusetts Stem Cell Bank

University of Tuebingen, Department of Medical
Genetics

US Biomax

Västerbotten County Council

ViaCord

Wellcome Trust

Wellcome Trust Case-Control Consortium (WTCCC)

Western Australian Genome Health Project

Wheaton Science International

Wisconsin International Stem Cell (WISC) Bank

World Health Organization (WHO)

Zhejiang Lukou Biotechnology Co 

To order this report:Blood Supply, Tissue Banking and Transplantation
Industry: Biobanking for Medicine: Technology and Market
2012-2022

More  

Market Research Report

Check our  

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

 

Read more from the original source:
Biobanking for Medicine: Technology and Market 2012-2022

26-01-2012 02:37 Animacel ltd. is offering your animal stem cell treatment with newly developed stem cell therapy. At the moment, excellent results are with treatments of different joint problems (arthritis and injury/damage of cartilage, hip dysplasia), tendon problems and supporting/adjuvant stem cell therapy for faster healing of broken bones. We are also developing treatment for heart insufficiency, eye dissease, diabetes, etc. See our webpage http://www.animacel.com

Read more:
Stem cell treatment for animals - Video

12-12-2009 13:45 What are stem cells? - An short educational film by the Irish Stem Cell Foundation Stem cells are master cells of the body — want to learn more? Visit http://www.irishstemcellfoundation.org ISCF is an independent not-for-profit organisation whose primary objective is to educate about stem cells, their basic biology and the research and therapies using them. The Foundation will initially focus on education outreach programs, hoping to address the growing problem of bogus stem cell scams being offered to Irish patients over the internet. The Foundation will also assist the development of Irish policy and legislature in this area of medicine and science, ensuring Ireland is informed. The Foundation consists of a broad range of people including Irish doctors, scientists, patient advocates, educators, bioethicists and other associated parties seeking to expand and develop the Irish public's understanding of stem cells.

See more here:
What are stem cells? How can they be used for medical benefit? - Video